Get started
Author

Urvashi Patel

Observed institution: Novavax (United States)
ORCID: 0000-0003-2995-1515
Observed ORCID: 0000-0003-2995-1515
OpenAlex ID: A5027600554
Severe Acute Respiratory Syndrome Coronavirus 2 Receptor (Human Angiotensin-Converting Enzyme 2) Binding Inhibition Assay: A Rapid, High-Throughput Assay Useful for Vaccine Immunogenicity Evaluation
2023 · Joyce S. Plested, Mingzhu Zhu, et al. · Microorganisms · 8
PDF
Detection of Anti‐SARS‐CoV‐2 Mucosal Immunoglobulin A in Clinical Saliva Samples After a Dose of Novavax COVID‐19 Vaccine
2025 · Mingzhu Zhu, Edmond Massuda, et al. · Journal of Medical Virology · 6
PDF
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine
2024 · Timothy S. Vincent, Mingzhu Zhu, et al. · Microorganisms · 5
Validation of a Mucosal IgA Assay for SARS-CoV-2
2026 · Mingzhu Zhu, Edmond Massuda, et al. · Microorganisms
Works count: 4
Citation count: 19
H-index: 3
I10-index:
Year
Topic
Type